The article reports on the development of certolizumab pegol in improving treatment for rheumatoid arthritis. It revealed that the agent showed improvements in rheumatoid arthritis symptoms. Meanwhile, UCB Pharma Inc. has submitted a marketing authorization application to the European Medicines Agency for the approval of the drug.